Press Releases | Gilead - Gilead Sciences
WEBJul 25, 2024 · Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024. January 22, 2024. Gilead Provides Update on Phase 3 EVOKE-01 Study. Read the latest news about Gilead's work in COVID-19, HIV, viral hepatitis, cancer and other areas.
Newsroom | Gilead - Gilead Sciences
WEBRecent Press Releases. September 12, 2024. Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial. September 10, 2024. Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies.
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
WEBFOSTER CITY, Calif., June 20, 2024 -- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial...
Gilead Sciences Expands Liver Portfolio With Acquisition of …
WEBFeb 12, 2024 · FOSTER CITY, Calif. & NEWARK, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
Gilead Lenacapavir cut HIV infections by 96% in trial - CNBC
WEBSep 12, 2024 · A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug. Gilead ’s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday ...
Gilead Unveils More Positive Data on HIV Prevention Shot - Barron's
WEBSep 12, 2024 · Gilead Sciences said that its twice-yearly shot lenacapavir reduced HIV infections by 96% in a large trial. The shot’s success could boost Gilead stock.
Gilead Sciences, Inc. (GILD) Stock Price, News, Quote & History
WEBFind the latest Gilead Sciences, Inc. (GILD) stock quote, history, news and other vital information to help you with your stock trading and investing.
Gilead Sciences Announces Second Quarter 2023 Financial Results
WEBAug 3, 2023 · Gilead Sciences Announces Second Quarter 2023 Financial Results. August 3, 2023. Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.3 billion. Biktarvy Sales Increased 17% Year-Over-Year to $3.0 billion. Oncology Sales Increased 38% Year-Over-Year to $728 million.
Gilead's breast cancer drug gets U.S. FDA approval for third …
WEBFeb 3 (Reuters) - Gilead Sciences (GILD.O) said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option...
Gilead Sciences Announces Fourth Quarter and Full Year 2023 …
WEBFeb 6, 2024 · Biktarvy® (bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 7% to $3.1 billion in the fourth quarter 2023 compared to the same period in 2022, primarily reflecting higher demand, partially offset by lower average realized price due to channel mix.